-
Hemp seed stocks bottomed out, and the market is expected to continue to rise!
Time of Update: 2022-09-06
Due to the low long-term price, the overall market attention of hemp seeds is limited, and the planting area of production areas has been shrinking in recent years .
-
In the next 3-5 years, China's innovative pharmaceutical companies will usher in a big test! How to deal with it?
Time of Update: 2022-09-06
" The industry said that with the increasing cost of innovative research and development and the low return on investment in the single market, the layout of pharmaceutical companies in the international market is a new way out, which is also conducive to enhancing the competitiveness of innovative enterprises.
-
The medical industry ushered in a major reshuffle and will gradually move from "barbaric growth" to standardized development
Time of Update: 2022-09-06
Recently, the Yunting Branch of the Jiangyin Municipal Supervision Bureau in Jiangsu Province has carried out in-depth special management of medical chaos and severely cracked down on violations of laws and regulations in the medical industry.
-
Mindray Medical was surveyed by 476 institutions in one week! Last week, institutions gathered to investigate pharmaceutical stocks
Time of Update: 2022-09-06
In the institutional survey, Kaili Medical said that in the first half of 2022, the company's various business developments are in line with the planning formulated at the beginning of the year, the ultrasound business grows steadily, the endoscopic business maintains a high growth rate, and the overall company's revenue increases significantly, and the net profit performance is better.
-
The rare disease drug market may approach 40 billion!
Time of Update: 2022-09-06
com, 53 rare disease drugs have been included in the national medical insurance, including human immunoglobulin, rosuvastatin, ezetimibe and other large varieties with terminal sales of over 1 billion yuan in China's public medical institutions in 2021 .
-
Tigermed, Kain Technology, Beida Pharmaceutical and other pharmaceutical companies have been rated as "buy" by institutions
Time of Update: 2022-09-06
The reasons for the rating mainly include: 1) Focus on innovative drugs, and the access of Kailiwei is progressing smoothly; 2) R&D investment continues to increase, accelerating the layout of hepatitis B functional cure pipeline; 3) Mature products JinShuxi and Kaiyin Yisheng maintain a high status.
-
The keel resources are exhausted, and the cost of raw materials for Jianmin Pharmaceuticals has greatly increased!
Time of Update: 2022-09-06
In this issue, Tiandi Yuntu Pharmaceutical Industry Big Data Platform analyzes the cost pressure of traditional Chinese medicine raw materials faced by enterprises from the perspective of the raw materials involved in its core product, Longmu Zhuanggu Granules .
-
Medical insurance, collection, national standard implementation... Opportunities and challenges coexist in the Traditional Chinese medicine formula granule industry
Time of Update: 2022-09-06
At the end of August, the Anhui Provincial Medical Insurance Bureau and other departments jointly issued a document to clearly include 343 Chinese medicine formula granules such as Poria (196 Chinese standards and 147 provincial standards) into the scope of medical insurance payment in Anhui Province.
-
FDA approves upgraded version of Moderna, Pfizer vaccines for certain populations
Time of Update: 2022-09-06
S. Food and Drug Administration on August 31 revised the emergency use authorization for Moderna and Pfizer’s new crown vaccines, approving certain age groups to receive upgraded versions of these two vaccines as booster shots to provide for the Omicron variant.
-
Notice of Issuing the Measures for the Administration of Network Security of Medical and Health Institutions
Time of Update: 2022-09-06
(5) In response to the hidden problems found in the rating evaluation, each medical and health institution shall formulate a network security rectification plan in accordance with the requirements of laws, regulations, policies and standards in accordance with external threats and risks, carry out targeted rectification, and eliminate hidden risks in a timely manner , strengthen management and technical shortcomings, and improve security protection capabilities .
-
Never allow oral implantation to become a "cash cow" related charges are planned to be specially treated
Time of Update: 2022-09-06
Centralized procurement and procurement squeeze out water and strengthen price abnormality warning Recently, the National Medical Security Bureau has solicited opinions from the public regarding the special treatment of dental implant medical service charges and consumable prices.
-
Heavy, the National Medical Insurance Bureau issued a document to support the pharmacy service fee!
Time of Update: 2022-09-06
Medicine Procurement Health On August 24, the National Medical Security Administration made an official reply to the proposal No. 7308 of the Fifth Session of the 13th National People's Congress - "Proposal on Implementing Pharmacy Service Fees as Soon as Possible to Give Full Play to the Power of Pharmacists" .
-
The innovation and development of the pharmaceutical equipment industry has become a trend Head enterprises have opened a large-scale expansion of talents
Time of Update: 2022-09-06
In recent years, with the rapid development of the pharmaceutical industry and the acceleration of innovation and upgrading, as well as the continuous breakthrough of emerging biotechnology in China, the promotion of emerging industries such as biomedicine and health industry, the market demand for high-end pharmaceutical equipment has been expanding.
-
"Countdown" to the reform of medical insurance accounts in many places!
Time of Update: 2022-09-06
In fact, since the State Council issued the "Guiding Opinions on Establishing and Improving the Outpatient Mutual Assistance Mechanism of Employee Basic Medical Insurance" (hereinafter referred to as the "Guiding Opinions") in April last year, the exploration of the reform of the employee medical insurance personal account system in various provinces and cities across the country is being carried out one after another.
-
Targeted use from September 1, how to use Beijing medical insurance personal account funds?
Time of Update: 2022-09-06
However, you can use your social security card to use your personal account (including mutual aid account) for payment, and the shortfall will be made up by the insured in cash .
-
The domestic antibacterial drug market has entered the market again, and it is predicted that the next 8 years may show a trend of first rising and then falling
Time of Update: 2022-09-06
【Pharmaceutical Network Market Analysis】 In the field of steady growth of antibacterial drugs, the author learned that a pharmaceutical company has recently ushered in.
【Pharmaceutical Network Market Analysis】 In the field of steady growth of antibacterial drugs, the author learned that a pharmaceutical company has recently ushered in.
-
There have been changes in the collection of proprietary Chinese medicines!
Time of Update: 2022-09-06
The time nodes of the purchase and sale agreement with the purchase and sale of pharmaceutical enterprises are as follows: Drugs On August 30, the Hunan Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of Centralized Procurement of Chinese Patent Medicines in Inter-Provincial Alliances" (hereinafter referred to as the "Notice"), announcing that the alliance will be launched on October 20.
-
The substitution of high-end imports of domestic pharmaceutical equipment has accelerated, and it has been shown in the performance of the head
Time of Update: 2022-09-06
In general, high-end has become the development direction of the biopharmaceutical equipment industry, and the enterprises represented by the head are expected to gradually break through the "card neck" link through continuous innovation and research and development, and accelerate import substitution with cost-effective advantages and tap more market space.
-
The medical insurance flight inspection found that the phenomenon of exceeding the medical insurance payment limit and other phenomena collectively "checked the pulse" to find the problem
Time of Update: 2022-09-06
(Zuo Handi on the website of the Central Commission for Discipline Inspection and State Supervision Commission) "Urine sediment quantitative examination is usually suitable for patients with urology, nephrology, obstetrics and renal disease, but all the patients admitted to the hospital have done this examination.
-
BeiGene, Junshi Bio and other leading innovative pharmaceutical companies are more willing to invest in this
Time of Update: 2022-09-06
Some institutions have released research reports saying that with the commercial expansion of BeiGene's core products BTK inhibitors and PD-1 monoclonal antibodies, as well as the expected milestones in the second half of 2022 (including the approval of new indications), BeiGene's globalization process will be verified, and it will also feed back early research and development investment through higher sales revenue.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
